MedTrace Logo

A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)

NCT01655992 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 386

Last updated 2018-01-23

No results posted yet for this study

Summary

Comparing S1 generic With Capecitabine in Patients With Metastatic Breast Cancer.

Conditions

Interventions

DRUG

capecitabine

2500mg／m2／day divided into twice two weeks on one week off

DRUG

S1 generic

40mg／m2 bid four weeks on two weeks off

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xi-chun Hu, MD,PhD · Fudan Univeristy Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01655992 on ClinicalTrials.gov